by
Gus Iversen, Editor in Chief | December 20, 2022
Fujifilm has announced an asset purchase agreement to acquire the digital pathology business of Inspirata, including Dynamyx, expanding its Synapse Enterprise Imaging offering to enable the integration of pathology images and data into a healthcare organization’s EHR system.
Dynamyx, which is FDA approved, can use whole slide images from multiple scanning vendors to create an easier path for more pathology labs to digitize and realize the benefits of faster results, centralized imaging records, and enterprise access to images. It is installed in medical facilities that handle large volumes of pathological images across multiple lab locations, allowing the use of their preferred mix of laboratory and diagnostic technologies with confidence of full compatibility.
“A $320 million global industry in 2021, projected to reach $640 million by 2025, the rising number of cancer cases and the demonstrated benefits of digital pathology are fueling significant demand and market growth in the hospital and pharmaceutical industries,” said Henry Izawa, president and CEO, Fujifilm Healthcare Americas Corporation, in a statement.
The vast majority of providers globally have yet to enter the digital pathology market, with 85% of U.S., 86% of European, and 90% of Asian healthcare organizations still running on analog, according to Fujifilm.
In August 2020, Fujifilm and Inspirata announced a commercial partnership allowing Fujifilm to supply and service Inspirata’s digital pathology workflow software globally and with exclusivity in the United Kingdom, Italy, Spain, Portugal, Belgium, the Netherlands, and Luxembourg.
“Since launching our European partnership with Inspirata three years ago, we’ve seen great success implementing our combined technologies in several healthcare organizations, notably in the U.K.,” says Masa Fukumoto, managing director, Fujifilm Healthcare Europe and senior vice president Fujifilm Medical Systems Europe. “We've received feedback from customers anticipating digitizing pathology will be the most transformative thing they do for their practice, and we look forward to continuing our global expansion.”
Timing for the completion of the transaction is subject to closing conditions and is scheduled for early 2023.
In March, Siemens Healthineers
extended its reach in the digital pathology market, combining its Syngo Carbon enterprise imaging solution with Proscia's Concentriq Dx digital pathology platform to meet the demands of pathologists whose legacy software systems lack the enterprise-wide capabilities needed to work efficiently in the digital era.
Back to HCB News
